Core Insights - Novo Nordisk is strengthening its leading position in the rapidly growing obesity treatment market by entering into a collaboration agreement with Deep Apple Therapeutics, valued at up to $812 million, to acquire small molecule drugs targeting non-insulin GPCR pathways [2][3] - This strategic partnership is part of Novo Nordisk's broader R&D investments aimed at securing next-generation metabolic disease therapies [2] Group 1: Collaboration Details - The agreement grants Novo Nordisk global licensing rights to Deep Apple's small molecule candidates aimed at an undisclosed non-insulin GPCR target, which has potential for treating obesity and other cardiometabolic diseases [3] - Deep Apple will be responsible for the discovery and optimization of candidate compounds, while Novo Nordisk will participate in early research plans and take over all development work before initiating clinical pre-IND studies [3] - This collaboration aligns with Novo Nordisk's recent strategy of acquiring early-stage, mechanism-diversified assets to enhance its long-term innovation capabilities [3] Group 2: Market Context and Challenges - The partnership follows underwhelming results from Novo Nordisk's next-generation obesity candidate CagriSema in Phase III clinical trials, which did not meet internal weight loss targets, allowing competitors like Eli Lilly to solidify their market position with tirzepatide [3] - In response to increasing competition, Novo Nordisk has accelerated investments in new projects, including a $50 million funding to Variant Bio, a $190 million collaboration with Valo Health, and a deal with Gensaic worth up to $354 million per target [4][5] Group 3: Strategic Shift - The collaboration with Deep Apple highlights Novo Nordisk's strategic shift towards non-insulin mechanisms and platform-driven innovation, as the company aims to lead the "second half" of obesity treatment through diversified mechanisms and cutting-edge research [7]

大家应该都听说了，国家正在大力推进"体重管理年"的相关举措吧？没错，如今国家正式发出号召，动员大家一起减肥。而且，这不仅仅是今 年的行动，未来很可能会持续成为每年的重点任务。 就在最近召开的全国两会上，国家卫生健康委员会主任雷海潮表示，今后将持续推动"体重管理年"相关工作。实际上，从2024年6月起，国家 卫健委就已经联合教育部、体育总局等多个部门，正式启动了为期三年的"体重管理年"专项行动。 去年年底，一场以体重管理年为主题的交流会上，国家心血管病中心健康生活方式医学中心常务副主任冯雪老师还特别指出，医生应该积极投 身健康科普，人人都要用写论文的劲头来普及健康知识，形成全民参与的科普合力。 说到底，减肥早已不仅仅是个人的事，现在已经上升为全社会的共同课题。查阅相关资料你会发现，肥胖问题影响深远。对个人来说，肥胖是 健康和身材的挑战；但当肥胖成为群体性问题时，甚至会对整个宏观经济产生影响。 别小看了这句话，这绝不是危言耸听。 ▍为什么说肥胖会影响宏观经济？ 什么是肥胖？目前国际通用的衡量标准主要有体脂率、腰围、腰臀比等，但最常见的还是体质指数（BMI）。BMI的计算方法是用体重（公 斤）除以身高（米）的平方。 ...

整理 | GLP1减重宝典内容团队 替尔泊肽的半衰期为 5 天。如果停止使用替尔泊肽，药物需要大约 30 天才能从您的体内排出。使用替尔泊肽并不能保证每周减掉一定量的体 重。但是， 专家建议每周减掉 1 到 2 斤是安全的减重速度 。 健康减肥需要时间。根据SURMOUNT-1试验，在开始使用替尔泊肽后的最初几周内，效果可能不明显。药物在第一次使用后开始起效，但减肥 效果不会立竿见影。 使用替尔泊肽的前四周内体重逐渐下降。 随着治疗的进展，减肥速度加快。 到第 12 周，研究显示 BMI 呈持续下降趋 势，此时平均体重比初始体重减少约 8%。 大约在第 24 周，当体重百分比变化达到约 12-15% 时， 最初的下降开始趋于平稳，速度更平缓 。在此阶段，当与健康饮食和定期锻炼相结合 时，替尔泊肽的效果是显而易见的。到这段时间结束时，患者很可能已经实现了很大一部分目标，为长期减肥奠定了基础。 点击关注，追踪最新GLP-1资讯 ▍ 可能影响替尔泊肽起效时间的因素 新陈代谢 脂肪肝、糖尿病等疾病会使减肥变得更加复杂，因为已经存在一定程度的代谢功能障碍。这些疾病往往伴有更严重的胰岛素抵抗，因此治疗起 来可能更困难或需 ...

Core Viewpoint - Zhang Yifan will officially join Lingbei China as General Manager on July 1, 2025, succeeding Jens Hoeyer, who has left the position [2][4][3]. Group 1: Leadership Transition - Zhang Yifan will be responsible for all operations of Lingbei in mainland China and Hong Kong, while Yang Shaohua will continue as Vice President focusing on strategic finance, business development, and partnerships [3][6]. - Yang Shaohua has played a crucial role in maintaining strong performance during the transition period [6]. Group 2: Zhang Yifan's Background - Zhang Yifan has 16 years of experience in the global pharmaceutical industry, including significant roles at Novo Nordisk in Denmark, France, Taiwan, and recently in China [5][8]. - He successfully built and led the obesity business unit from scratch in China, launching new products nationwide [5][8]. - Zhang holds a Master's degree in International Business and Trade from the University of Gothenburg, Sweden, and a Bachelor's degree in International Business from Brisbane, Australia [5][8]. Group 3: Future Outlook - The leadership believes that Zhang's extensive cross-functional and regional experience, along with his strategic thinking and management skills, will drive Lingbei China towards its goal of becoming an "innovation-focused" company [5][8].

Core Viewpoint - The article discusses the implications of pausing the use of semaglutide and provides guidance on how to do so safely while maintaining weight management and health benefits [2]. Summary by Sections Timeline: What Happens After Injecting Semaglutide - 1-2 hours: The drug begins to be absorbed into the bloodstream after subcutaneous injection [6]. - 24-48 hours: Peak concentration in the blood is reached, actively binding to GLP-1 receptors [7]. - 1-2 weeks: Initial noticeable effects such as reduced appetite and improved blood sugar regulation may begin [8]. - 4-5 weeks: Steady-state levels are achieved, leading to more pronounced appetite suppression and accelerated weight loss [9]. Best Way to Pause Medication - It is recommended to start with the lowest dose and gradually increase it over months to minimize potential side effects. Sudden discontinuation does not typically cause withdrawal symptoms [10]. - Gradually reducing the dose is advised to mitigate increased hunger that may occur after stopping the medication [12]. - Adjusting injection intervals can help manage the pause: minimum 2 days between injections or less than 12 days for extending the cycle [12]. Effects After Stopping Medication - A 2021 clinical trial showed that participants lost an average of 10.6% of their weight during treatment, but those switched to a placebo regained an average of 6.9% of their weight [13]. - An observational study indicated that 18% of patients regained their lost weight after one year off the medication, while 26% regained more than 25% of their lost weight [13]. Importance of Continuing Medication - The STEP 5 trial demonstrated that continuous use of semaglutide for 2 years resulted in a weight loss of 15.2% compared to placebo [16]. - The SELECT trial showed that patients maintained an average weight loss of about 10% over 4 years, emphasizing the chronic nature of obesity and the need for long-term management [16]. Obesity as a Chronic Disease - Recent studies confirm obesity as a chronic disease, with 76.8% of patients and 94.6% of doctors agreeing on its classification [17]. - Obesity leads to various health issues, increasing the risk of type 2 diabetes and cardiovascular diseases, necessitating its inclusion in chronic disease management [17]. Weight Loss and Chronic Complications - Weight loss of 5% can improve hypertension and blood sugar levels, while a 10-15% reduction significantly lowers the risk of cardiovascular diseases and other complications [19]. - Overall, weight loss interventions can substantially reduce the risk of chronic complications and improve health outcomes for obese patients [19].

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity crisis and the necessity for innovative solutions that integrate technology, policy, and community efforts [3][5][18]. Group 1: Obesity Crisis and Health Implications - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [3]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, while youth rates may hit 31.8% [3]. - Obesity is linked to over 200 diseases, leading to annual medical expenditures exceeding 240 billion yuan [5]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes the goal of "muscle gain and fat loss," moving away from the sole reliance on BMI for health assessments [6]. - Innovative products, such as a patented CLA+ whey protein blend, have shown promising results in trials, with users gaining an average of 2.3 kg of muscle and losing 4.7 kg of fat over three months [6]. - The "Metabolic Map" project aims to utilize wearable devices to monitor metabolic health indicators, enhancing personalized health management [7]. Group 3: New Approaches to Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks to address obesity linked to microbiome imbalances [8]. - A combination of prebiotics and postbiotics has been developed to promote beneficial gut bacteria, resulting in an average waist reduction of 5 cm and a 23% improvement in skin elasticity among users [8]. - The integration of skin-tightening treatments post-weight loss is gaining traction, with satisfaction rates as high as 91% for skin recovery services [9]. Group 4: Addressing Market Challenges - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [12]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals adhering to obesity treatment guidelines and a severe shortage of specialized weight loss surgeons [13]. Group 5: Future of Weight Management - The future of weight management is expected to leverage advanced technologies such as AR body fat scanning and AI-driven personalized plans, making weight loss more intelligent and effective [17]. - A collaborative approach involving government, businesses, and communities is essential to create a supportive environment for health initiatives [17]. - The narrative of weight management is shifting from mere calorie restriction to a more nuanced understanding of muscle and fat regulation, gut health, and the integration of technology in health practices [18].

Core Viewpoint - Mounjaro has gained unprecedented attention as an effective solution for sustainable weight loss, initially developed for treating type 2 diabetes, and has proven effective in controlling blood sugar and aiding weight loss [2] Group 1: Clinical Trial Data - Mounjaro's effectiveness is highlighted by the SURMOUNT-5 phase 3b clinical trial, where participants lost an average of 50.3 pounds (22.8 kg) over 72 weeks [4] - Experts in obesity medicine regard Mounjaro as a groundbreaking drug that effectively combines weight loss and metabolic health improvement [4] Group 2: Mechanism of Action - Mounjaro employs a dual-target mechanism, utilizing GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) to regulate appetite, improve blood sugar control, and enhance fat reduction [5] - This multi-target approach is believed to contribute to the long-term effectiveness of weight management for many patients [5] Group 3: Health Benefits Beyond Weight Loss - Mounjaro has shown improvements in metabolic indicators such as blood pressure, blood lipids, BMI, and waist circumference, which are critical risk factors for cardiovascular diseases [6] - The drug has been approved for treating moderate to severe obstructive sleep apnea (OSA) in obese adults, linking weight loss to potential benefits for OSA patients [8] - Positive results from the SUMMIT study indicate that Mounjaro significantly reduces the risk of heart failure in patients with preserved ejection fraction [8] Group 4: Future Outlook - The obesity epidemic poses significant health risks and economic burdens, with studies indicating that individuals with a BMI of 40-50 kg/m² have only a 50% chance of living to 70 years old [11] - Effective weight loss interventions can significantly reduce the risk of related complications, such as type 2 diabetes and sleep apnea, by over 50% for patients without existing complications [11] - Experts believe that advancements in weight loss science may lead to a turning point in the battle against obesity [11]

Core Viewpoint - The article discusses the rising popularity of intermittent fasting, particularly the 5:2 fasting method, as an effective weight loss strategy endorsed by various celebrities and public figures [4][5][6]. Group 1: Celebrity Endorsements - In 2023, notable figures like Trump and Musk successfully lost significant weight using intermittent fasting, with Trump losing 25 pounds (approximately 11 kg) and Musk losing 20 pounds (approximately 9 kg) [4]. - Celebrities such as Chris Pratt and Kim Kardashian have also adopted this weight loss method, integrating it into their daily routines [4]. Group 2: Intermittent Fasting Overview - The method gaining traction is "intermittent fasting," specifically the 5:2 fasting approach, which involves normal eating for five days and fasting for two non-consecutive days each week [5][6]. - This method is accessible to most individuals without severe chronic illnesses and is designed to improve insulin sensitivity and reduce the risk of cardiovascular diseases [6]. Group 3: 5:2 Fasting Method - The 5:2 fasting method is simple: eat normally for five days and restrict calorie intake to 800 calories on fasting days, following a Mediterranean diet [6][9]. - Research from Newcastle University indicates that individuals following the 800-calorie diet can lose an average of 10.8 kg over eight weeks while also improving conditions like hypertension and type 2 diabetes [9]. Group 4: Additional Fasting Methods - Besides the 5:2 method, the 16:8 fasting approach (16 hours fasting, 8 hours eating) is also popular among celebrities, though it may require more caution for individuals over 60 [14]. - An alternative is the 14:10 fasting method, which is safer and still effective, achieving about 80-90% of the results of the 16:8 method [14]. Group 5: Enhancing Weight Loss - The article suggests three "weight loss enhancers" to complement intermittent fasting: 1. Engaging in 5 minutes of light exercise daily, such as HIIT, can significantly boost weight loss efficiency [19][21]. 2. Adequate calcium intake is crucial for effective fat burning, with studies showing a potential weight loss of 7 kg over 25 weeks with daily calcium supplementation [22]. 3. Balancing hormone levels is essential for weight management, with dietary recommendations for both men and women to support hormonal health [23].

Core Viewpoint - Eli Lilly's dual receptor agonist, Tirzepatide injection, has had its new indication application accepted by the National Medical Products Administration, with speculation that it targets obstructive sleep apnea (OSA), potentially making it the first drug in China specifically for OSA treatment [2]. Group 1: Drug Development and Approvals - Tirzepatide is a GLP-1 and GIP dual receptor agonist that regulates appetite, energy intake, and metabolic function [2]. - The drug was approved by the FDA in the U.S. in May 2022 for diabetes treatment under the brand name Mounjaro® [2]. - In November 2023, it received approval for weight loss and is expected to be approved for moderate to severe OSA treatment by December 2024, marketed as Zepbound® [2]. - In China, Tirzepatide's diabetes indication was approved on May 21, 2024, and the weight loss indication was approved on July 19, 2024, both under the brand name "穆峰达®" [4]. Group 2: Market Potential and Applications - Eli Lilly is expanding Tirzepatide's clinical applications beyond diabetes and weight loss to include cardiovascular diseases, chronic kidney disease, and non-alcoholic fatty liver disease (NASH), targeting a total of nine chronic disease areas [4]. - OSA is a common sleep-related breathing disorder that can lead to various cardiovascular and metabolic diseases, including hypertension, coronary heart disease, stroke, heart failure, atrial fibrillation, and type 2 diabetes [2].

Core Viewpoint - The article emphasizes the launch of a three-year "Weight Management Year" initiative by the National Health Commission to address the increasing issues of overweight and obesity in China, promoting scientific weight loss and healthy lifestyles [3][4]. Group 1: Current Situation of Overweight and Obesity - The report indicates that the overweight and obesity rates among Chinese youth aged 6-17 have reached 19%, while the adult population's rate stands at 50.7% [5]. - Over the past 15 years, the obesity rate among adolescents has surged by 12 times, with workplace-related obesity and elderly obesity becoming more prevalent [5]. - Chronic diseases related to obesity, such as hypertension, diabetes, and cardiovascular diseases, account for over 70% of the national disease burden, with direct medical expenses exceeding 240 billion yuan annually [5]. Group 2: Obesity Assessment Criteria - Obesity is primarily assessed using BMI and waist circumference metrics, with a normal BMI range defined as 18.5 to 23.9 [6]. - Waist circumference is a critical indicator of abdominal obesity, with men exceeding 90 cm and women exceeding 85 cm at risk [8]. - Other common obesity assessment indicators include body fat percentage and waist-to-hip ratio, with specific thresholds indicating obesity risk [9]. Group 3: Consequences of Obesity - Obesity is linked to increased body weight and is closely associated with blood sugar and lipid levels, leading to insulin resistance and elevated blood sugar, which can progress to diabetes [10]. - It is also a significant risk factor for dyslipidemia, with excess body fat leading to abnormal blood lipid levels [11]. - Regular monitoring of blood sugar and lipid levels is essential, even for individuals with a normal BMI, to ensure metabolic health [12]. Group 4: Multi-Dimensional Weight Management Strategies - Enhancing basal metabolic rate (BMR) through muscle gain and regular exercise is crucial for effective weight management [13]. - B vitamins play a vital role in energy metabolism, influencing both basal and activity metabolic rates, and their deficiency can lead to metabolic disorders [14]. - Reducing exposure to toxic elements and endocrine disruptors is important for maintaining metabolic balance and preventing obesity [15]. Group 5: Gut Health and Digestion - A healthy gut is essential for nutrient absorption and waste elimination, with gut microbiota playing a significant role in weight regulation [17]. - Hormonal balance, regulated by the endocrine system, is critical for metabolism and energy management, with disruptions potentially leading to obesity [17]. - A balanced diet, incorporating various nutrients, is fundamental for effective weight management and healthy weight loss [17].